📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-01 15:49
0 analysed today
0
Today
133,620
All-time analysed
40,132
Positive
6,284
Negative
79,384
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
32 announcements match the current filters (relevance ≥ 5).
USFDA Concludes GMP Inspection at Vizag Sterile Oncology & API Facility with Zero Form 483 Observations
The United States Food and Drug Administration (USFDA) conducted a routine Good Manufacturing Practice (GMP) inspection at Gland Pharma's VSEZ Sterile Oncology Formulations and API facility in Visakhapatnam between August 24, 2026, and September 01, 2026. The inspection successfully concluded with zero (0) Form 483 observations. This clean outcome mitigates US regulatory risk for a key sterile injectable and API manufacturing site.
Confidence: HIGH
What changedUSFDA concluded its GMP inspection of the Visakhapatnam sterile oncology and API site without issuing any Form 483 observations.
Why it mattersA clean audit for complex sterile injectable and API facilities prevents supply disruptions and supports continued regulatory approvals for the US market.
Form 483 Observations: 0Inspection Start Date: August 24, 2026Inspection End Date: September 01, 2026TTM Revenue Context: ₹6,431 Cr
📅 Short termRemoves immediate regulatory compliance overhang for the Vizag facility, boosting operational confidence.
📈 Long termReaffirms strong compliance standards for US injectable supplies and provides stability for oncology formulations and API exports.
⚠ Risk flags
- Formal Establishment Inspection Report (EIR) closure pending issuance by USFDA
Key Highlights
USFDA routine GMP inspection conducted from August 24, 2026 to September 01, 2026
Inspection concluded with ZERO (0) Form 483 observations
Covers both the VSEZ Sterile Oncology Formulations Facility and API Facility at Visakhapatnam
No violations, contraventions, or adverse operational impacts reported
👀 What to Watch
Track receipt of the formal Establishment Inspection Report (EIR) classification from the USFDA and subsequent product approval traction from this facility.
Q1 FY27 Earnings Call: Revenue Up 20% to ₹1,800 Cr, PAT Surges 47% to ₹317 Cr
Gland Pharma filed the transcript of its Q1 FY27 earnings conference call held on August 10, 2026. The company reported consolidated revenue of INR 18,003 million (₹1,800.3 Cr), marking a 20% YoY growth driven by strength in CDMO and B2B segments. Adjusted EBITDA reached INR 5,102 million with a 28% margin, while PAT grew 47% YoY to INR 3,170 million (18% margin). Management also highlighted its Novel Drug Delivery Systems (NDDS) pipeline, projecting commercialization by 2029 with an estimated USD 25-30 million revenue potential.
Confidence: HIGH
What changedSubmission of the official earnings call transcript for Q1 FY27.
Why it mattersProvides granular operational insights into core B2B/CDMO volume growth, pricing resilience, profit share contributions, and strategic project timelines.
Q1 FY27 Revenue: INR 18,003 millionQ1 FY27 Adj. EBITDA: INR 5,102 millionAdj. EBITDA Margin: 28%Q1 FY27 PAT: INR 3,170 millionPAT Growth YoY: 47%NDDS Revenue Potential: USD 25 million to USD 30 million
📅 Short termConfirms strong operating leverage and efficiency gains achieved in the first quarter.
📈 Long termExpansion into complex injectables, GLP-1 capacity, and the planned NDDS rollout support multi-year growth visibility.
⚠ Risk flags
- Regulatory compliance across sterile injectable facilities
- Dependency on timing of US partner tech transfers and licensing revenue volatility
Key Highlights
Q1 FY27 revenue grew 20% YoY to INR 18,003 million (approx. ₹1,800.3 Cr)
Adjusted EBITDA stood at INR 5,102 million with a healthy margin of 28%
Net profit (PAT) increased 47% YoY to INR 3,170 million with an 18% margin
Profit share accounted for approximately 9% of total revenue during the quarter
NDDS project scheduled for execution by 2028 and commercial launch in 2029 with USD 25M to 30M potential
👀 What to Watch
Track capacity utilization, Cenexi operational turnaround, and execution milestones for complex injectable launches and the NDDS pipeline.
Gland Pharma Appoints Dr. Reddy's Veteran Deepak Sapra as CEO Effective Nov 16, 2026
Gland Pharma has announced the appointment of Mr. Deepak Sapra as its new Chief Executive Officer, effective November 16, 2026. Mr. Sapra is a high-profile hire, currently serving as the CEO of API and Services at Dr. Reddy’s Laboratories. With 27 years of executive experience, his background in CDMO services and global portfolio strategy aligns with Gland's current focus on complex injectables and the Cenexi integration. This leadership transition is significant for a company with a market cap of ₹48,904 Cr and TTM revenue of ₹6,431 Cr.
Confidence: HIGH
What changedGland Pharma has secured a seasoned industry leader from a major peer (Dr. Reddy's) to lead the company starting in late 2026.
Why it mattersLeadership stability and expertise are crucial as Gland Pharma navigates the turnaround of Cenexi and shifts toward a differentiated complex injectable portfolio to sustain its 25.3% operating margins.
Effective Date: November 16, 2026Executive Experience: 27 yearsTTM Revenue: ₹6,431 CrMarket Cap: ₹48,904 Cr
📅 Short termThe market is likely to view the appointment of a veteran from a top-tier firm like Dr. Reddy's as a positive signal for long-term governance and strategy.
📈 Long termMr. Sapra's extensive experience in CDMO and global markets is structurally significant for Gland's goal of expanding its complex injectable and GLP-1 manufacturing capabilities.
⚠ Risk flags
- Long lead time until the effective date (Nov 2026)
- Execution risk during the leadership transition
Key Highlights
Mr. Deepak Sapra to take over as CEO starting November 16, 2026
Brings 27 years of executive experience, including 23 years specifically in the pharmaceutical sector
Currently leads the integrated B2B business at Dr. Reddy’s Laboratories spanning APIs and CDMO services
Proven track record in M&A and portfolio creation across major markets including the US, EU, and China
Appointment is subject to his formal acceptance of the offer made by the company
👀 What to Watch
Investors should monitor the transition period and look for any strategic updates regarding the CDMO business and GLP-1 capacity expansion once the new leadership takes charge in late 2026.
47% YoY PAT Growth in Q1 FY27; Revenue up 20% to ₹1,800 Cr
Gland Pharma reported a strong start to FY27 with consolidated revenue growing 20% YoY to ₹18,003 Mn, primarily driven by a 32% surge in the US market. Net profit (PAT) increased 47% YoY to ₹3,170 Mn, with PAT margins expanding from 14% to 18% YoY. While YoY performance was robust, the company saw a 14% sequential decline in PAT compared to Q4 FY26. The US market remains the dominant contributor at 54% of total revenue, supported by new launches like Dalbavancin and volume expansion in existing products.
Confidence: HIGH
What changedThe company has demonstrated strong YoY recovery in its core US and Europe markets, offsetting a 28% YoY decline in other core markets like Canada and Australia.
Why it mattersThe results indicate a stabilization of the B2B and CDMO segments and successful new product launches, which are critical for maintaining the company's high P/E valuation of 46.9.
Revenue (Q1 FY27): ₹18,003 MnPAT (Q1 FY27): ₹3,170 MnUS Revenue Growth (YoY): 32%EBITDA Margin: 27%R&D Expenditure: ₹772 MnQ1 Revenue vs TTM Revenue: 28.0%
📅 Short termThe strong YoY growth figures are likely to be viewed positively by the market, though the sequential dip in PAT and margins may lead to some consolidation.
📈 Long termThe structural shift towards a differentiated complex portfolio and expansion into GLP-1 capacity remains the key long-term growth driver.
⚠ Risk flags
- Sequential decline in PAT (-14%) and EBITDA margins
- 28% YoY revenue decline in Canada, Australia, and New Zealand markets
- Milestone revenue volatility
Key Highlights
Revenue from operations grew 20% YoY to ₹18,003 Mn, representing ~28% of TTM revenue.
US market revenue increased 32% YoY to ₹9,810 Mn, driven by CDMO launches and B2B volume expansion.
PAT rose 47% YoY to ₹3,170 Mn, though it declined 14% sequentially from ₹3,667 Mn in Q4 FY26.
EBITDA margins improved to 27% in Q1 FY27 compared to 24% in Q1 FY26.
US filings update: Received 7 ANDA approvals in Q1, bringing the cumulative total to 342 approved ANDAs.
👀 What to Watch
Investors should monitor the sustainability of the US growth momentum and the sequential margin pressure (EBITDA margin fell from 29% in Q4 FY26 to 27% in Q1 FY27). Watch for progress in the complex injectable pipeline and the turnaround of the Cenexi business in Europe.
47% YoY PAT Growth for Gland Pharma in Q1FY27; Revenue Rises 20% to ₹1,800 Cr
Gland Pharma reported a strong start to FY27 with Q1 revenue growing 20% YoY to ₹1,800.3 Cr. Net profit (PAT) surged 47% YoY to ₹317 Cr, driven by a 330 bps expansion in PAT margins to 18%. The CDMO segment performed robustly, contributing 50% of total revenue and growing 20% YoY. However, on a sequential basis, PAT declined 14% from ₹366.7 Cr in Q4FY26, reflecting some quarterly volatility.
Confidence: HIGH
What changedGland Pharma has demonstrated strong YoY recovery in margins and revenue, successfully balancing its CDMO and B2B portfolios.
Why it mattersThe significant margin expansion and 20% growth in the CDMO business validate the company's shift toward a differentiated complex injectable portfolio, which is higher margin than standard generics.
Q1FY27 Revenue: ₹1,800.3 CrQ1FY27 PAT: ₹317.0 CrYoY Revenue Growth: 20%YoY PAT Growth: 47%EBITDA Margin: 27%R&D Investment: ₹77.2 Cr
📅 Short termThe stock may react positively to the strong YoY growth and margin improvement, although the sequential (QoQ) dip in PAT might lead to some consolidation.
📈 Long termStructural growth remains supported by the expansion into GLP-1 and complex injectables, alongside the integration of Cenexi to reach EBITDA breakeven.
⚠ Risk flags
- Sequential decline in PAT (-14%) and EBITDA (-4%)
- Milestone revenue volatility
- Execution risk in complex technology transfers
Key Highlights
Revenue from operations increased 20% YoY to ₹1,800.3 Cr, representing ~28% of TTM revenue.
PAT grew 47% YoY to ₹317 Cr, though it declined 14% sequentially from Q4FY26.
Adjusted EBITDA margin improved to 28% compared to 25% in the same quarter last year.
CDMO and B2B segments each contributed 50% to the total revenue mix.
Quarterly R&D investments stood at ₹77.2 Cr, supporting a robust complex injectable pipeline.
👀 What to Watch
Watch for the upcoming earnings call details regarding the turnaround of Cenexi and the execution timeline for the new GLP-1 capacity expansion.
Gland Pharma Q1 FY27 Revenue grows 19.6% YoY to ₹1,800 Cr; US Market surges 32%
Gland Pharma reported a robust Q1 FY27 with total revenue reaching ₹1,800.3 cr, a 19.6% increase from ₹1,505.6 cr in Q1 FY26. The US market, which contributes 54% of total revenue, was the primary driver with 32% YoY growth to ₹981 cr, supported by new launches like Dalbavancin. Europe also showed steady performance with 20% growth to ₹395.4 cr. However, 'Other Core Markets' (Canada, Australia, NZ) saw a 28% revenue decline due to volume drops in existing products.
Confidence: HIGH
What changedGland Pharma reported its Q1 FY27 financial results, showing strong double-digit growth in its key US and European markets compared to the previous year.
Why it mattersThe recovery in the US market (54% of revenue) and successful new launches validate the company's strategy to shift toward complex injectables and CDMO services.
Q1 FY27 Revenue: ₹1,800.3 crUS Revenue Growth (YoY): 32%Europe Revenue Growth (YoY): 20%ANDA Approvals (Q1): 7 unitsRevenue vs TTM Revenue: ~28%
📅 Short termThe stock is likely to react positively to the strong top-line growth and the significant recovery in the US market segment.
📈 Long termStructural growth depends on the successful integration of Cenexi and the ramp-up of complex injectable manufacturing, including GLP-1 and pen-device systems.
⚠ Risk flags
- Volume decline in Canada/Australia/NZ markets (-28% YoY)
- Milestone revenue volatility
- Cenexi integration and EBITDA breakeven timing
Key Highlights
US market revenue grew 32% YoY to ₹981 cr, driven by new product launches and volume expansion in B2B products.
Europe revenue increased 20% YoY to ₹395.4 cr, supported by Cenexi CDMO products and Daptomycin volumes.
Received 7 new ANDA approvals in Q1 FY27, bringing the cumulative total to 342 approved filings.
India CDMO revenue surged 56% YoY to ₹48.3 cr, partially offsetting a 36% decline in B2B sales of Enoxaparin.
Launched 4 new molecules in the US market during the quarter, including Dalbavancin and Multi-Vitamin.
👀 What to Watch
Monitor the EBITDA breakeven progress of the Cenexi acquisition (targeting a EUR 50 million revenue run rate) and the commercialization timeline for the new GLP-1 manufacturing capacity.
USD 90-100M Annual Revenue Potential from New Strategic CDMO Partnership
Gland Pharma has signed a strategic Manufacturing and Supply Agreement (MSA) with a leading global pharmaceutical company for a portfolio of 55 sterile injectable SKUs. The partnership follows a full-service CDMO model covering technology transfer, commercial manufacturing, and long-term supply across three sites. While technology transfer will take two years, commercial revenue is expected to commence in CY 2029. The annualized revenue potential of USD 90-100 million represents approximately 12-13% of the company's current TTM revenue.
Confidence: HIGH
What changedGland Pharma has transitioned from a standard B2B provider to a strategic long-term CDMO partner for a major global pharma player, securing a significant future revenue stream.
Why it mattersThis deal provides long-term revenue visibility and validates Gland's capabilities in complex injectables and 'one-stop' CDMO services, which is critical for its growth strategy and P/E re-rating.
Annualized Revenue Potential: USD 90-100 millionRevenue Potential vs TTM Revenue: ~12.9%Number of SKUs: 55Revenue Commencement: CY 2029Tech Transfer Timeline: 2 years
📅 Short termThe stock may see positive sentiment as this deal provides a clear long-term growth lever, although there is no immediate impact on the current fiscal year's P&L.
📈 Long termStructurally significant as it builds a high-margin, predictable revenue base for the next decade, diversifying away from volatile milestone-linked income.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Long gestation period (revenue starts only in 2029)
- Execution risk during the 2-year technology transfer phase
- Partner identity remains confidential
Key Highlights
Annualized revenue potential estimated at USD 90–100 million once all products are commercialized
Agreement covers 55 SKUs including oncology and non-oncology products in Vial, Lyo, Ampoule, and PFS formats
Revenue generation is anticipated to start from calendar year 2029 following a 2-year tech transfer phase
Manufacturing will be spread across three of Gland Pharma's existing sites
Partnership includes both currently marketed products and pipeline products under development
👀 What to Watch
Watch for updates on the completion of technology transfer milestones over the next 24 months and any potential expansion of the SKU count within this partnership.
$90-100M Annual Revenue Potential: Gland Pharma Signs Strategic CDMO Deal for 55 SKUs
Gland Pharma has entered into a strategic Manufacturing and Supply Agreement (MSA) with a leading global pharmaceutical company for a portfolio of sterile injectables. The partnership covers 55 SKUs across oncology and non-oncology segments, including complex formulations like pre-filled syringes and lyophilized vials. While technology transfer will take approximately two years, the company expects an annualized revenue potential of $90-100 million once fully commercialized. This represents a significant long-term addition, equivalent to approximately 12-13% of the company's current TTM revenue of Rs 6,431 crore.
Confidence: HIGH
What changedGland Pharma has secured a major long-term CDMO contract, shifting from a standard generic manufacturer to an integrated end-to-end partner for a global pharmaceutical major.
Why it mattersThis deal provides high long-term revenue visibility and validates Gland's capabilities in complex injectables and multi-site manufacturing, which is critical for its CDMO growth strategy.
Annualized Revenue Potential: USD 90-100 millionNumber of SKUs: 55Est. Revenue vs TTM Revenue: ~12-13%Revenue Start Year: CY 2029Manufacturing Sites Involved: 3
📅 Short termThe news is likely to be viewed positively by the market as it secures future growth, though there will be no immediate impact on the P&L for the next 2-3 years.
📈 Long termStructurally significant as it builds a massive revenue base for the end of the decade and strengthens Gland's position in the high-margin complex injectables CDMO market.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Long gestation period (3 years until revenue)
- Execution risk during technology transfer
- Client concentration risk (name not disclosed)
Key Highlights
Annualized revenue potential estimated at USD 90–100 million upon full commercialization
Agreement covers a diversified basket of 55 SKUs to be manufactured across three sites
Technology transfer activities are planned for completion within a 2-year timeline
Revenue generation from this partnership is anticipated to commence from calendar year 2029
Portfolio includes oncology and non-oncology products in Vial, Lyo, Ampoule, and PFS presentations
👀 What to Watch
Investors should monitor the execution of technology transfers over the next 24 months and watch for any expansion in the number of SKUs, which the company indicated is possible.
Gland Pharma & Neuland Labs Partner for 1400 kg Sterile API Capacity Expansion
Gland Pharma and Neuland Laboratories have entered into a long-term strategic CDMO partnership to manufacture sterile APIs for microparticle depot products. Gland will establish a new, dedicated sterile manufacturing suite at its JNPC facility in Visakhapatnam with an annual capacity of approximately 1400 kg. This collaboration leverages Neuland's complex API development expertise and Gland's sterile manufacturing and regulatory track record. The facility will be built to USFDA and EU standards to serve global demand for complex injectable therapies.
Confidence: HIGH
What changedGland Pharma is expanding its manufacturing infrastructure to include a dedicated sterile API suite specifically for a strategic partnership with Neuland Laboratories.
Why it mattersThis move strengthens Gland's position in the high-margin complex injectable CDMO market and provides vertical integration benefits for specialized products like microparticle depots.
Annual capacity added: 1400 kgTTM Revenue: ₹6431 CrMarket Cap: ₹41941 CrPromoter Holding: 51.8%
📅 Short termThe announcement is likely to be viewed positively by the market as it involves a strategic tie-up between two well-regarded pharmaceutical companies in a high-value niche.
📈 Long termThis partnership builds a foundation for sustainable growth in the complex injectable space, potentially improving Gland's margin profile as it moves into more specialized CDMO offerings.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk in facility construction
- Regulatory approval timelines for the new suite
- Dependence on Neuland's demand growth for these specific APIs
Key Highlights
Establishment of a new dedicated sterile manufacturing suite at Gland's Visakhapatnam facility.
The new suite is designed to add approximately 1400 kg of annual capacity for sterile APIs.
Focus on microparticle depot products, a high-barrier segment of the complex injectable market.
Long-term strategic CDMO partnership combining Neuland's chemistry expertise with Gland's manufacturing scale.
Facility will be operated to cGMP, USFDA, and EU standards for global supply resilience.
👀 What to Watch
Monitor the construction timeline for the Visakhapatnam suite and the subsequent USFDA/EU regulatory inspection schedule. Watch for future disclosures on the capital expenditure (Capex) and the expected revenue ramp-up from this partnership.
Rs 20 Dividend: Gland Pharma Sets 48th AGM Date and Record Date for FY26
Gland Pharma has announced its 48th Annual General Meeting (AGM) scheduled for August 25, 2026. The company has confirmed a final dividend of Rs 20 per share for the financial year 2025-26. The record date to determine shareholder eligibility for this dividend is August 11, 2026, with the payment to be completed by September 24, 2026. This announcement follows a fiscal year where the company reported a TTM PAT of Rs 1,028 Cr.
Confidence: HIGH
What changedThe company has formalized the timeline for its 48th AGM and the distribution of its FY26 final dividend.
Why it mattersThis is a routine but necessary administrative update that confirms the cash outflow for dividends and provides the schedule for shareholder voting on corporate resolutions.
Dividend per share: Rs 20Dividend Yield: 0.80%Record Date: August 11, 2026AGM Date: August 25, 2026TTM PAT: Rs 1028 Cr
📅 Short termThe stock may see minor activity around the record date as investors position for the Rs 20 dividend payout.
📈 Long termLimited structural significance as this is a routine annual compliance and dividend distribution event.
Key Highlights
Final dividend of Rs 20 per share declared for FY 2025-26
Record date for dividend entitlement set for August 11, 2026
48th Annual General Meeting scheduled for August 25, 2026, at 11:00 AM IST
Remote e-voting period spans from August 22, 2026, to August 24, 2026
Dividend payment to be processed on or before September 24, 2026
👀 What to Watch
Investors should note the record date of August 11, 2026, for dividend eligibility and may review the full Annual Report for management's commentary on GLP-1 capacity expansion and Cenexi's turnaround progress.
Gland Pharma announces ₹20/share dividend; 48th AGM scheduled for August 25, 2026
Gland Pharma has issued the notice for its 48th Annual General Meeting (AGM) to be held on August 25, 2026. The company has recommended a final dividend of ₹20 per equity share for FY26, with the record date set for August 11, 2026. This dividend represents a payout of approximately ₹330 crore, which is roughly 32% of the FY26 PAT of ₹1,028 crore. The meeting will also cover the reappointment of two directors and the adoption of audited financial statements.
Confidence: HIGH
What changedFormalization of the 48th AGM schedule and confirmation of the ₹20 per share dividend record date.
Why it mattersThe dividend provides a tangible cash return to shareholders, representing a ~0.8% yield at current prices, and the AGM serves as the primary forum for adopting the FY26 financial results.
Final Dividend: ₹20 per shareRecord Date: August 11, 2026Dividend vs FY26 PAT: ~32%Dividend Yield: ~0.8%Paid-up Capital: ₹16,49,59,682
📅 Short termThe stock may see mild support as it approaches the dividend record date in mid-August.
📈 Long termLimited; this is a routine annual administrative and payout event with no structural change to business operations.
Key Highlights
Final dividend of ₹20 per equity share (Face Value ₹1) recommended for FY26
Record date for dividend eligibility fixed as August 11, 2026
AGM scheduled for August 25, 2026, at 11:00 AM IST via video conferencing
E-voting period set from August 22, 2026, to August 24, 2026
Reappointment of directors Mr. Wenjie Zhang and Ms. Wei Huang proposed
👀 What to Watch
Investors should note the record date of August 11, 2026, for dividend eligibility and may review the Annual Report for updates on the Cenexi integration and GLP-1 capacity expansion progress.
Gland Pharma receives USFDA approval for Sugammadex Injection; US market size $1.6 billion
Gland Pharma has received USFDA approval for Sugammadex Injection (generic Bridion®), used to reverse neuromuscular blockade during surgery. The company has already executed a 'Day 1' launch through its marketing partner. According to IQVIA, the US market for this molecule is approximately $1.6 billion for the 12 months ending April 2026. This represents a significant opportunity given Gland's TTM revenue of Rs 6,431 Cr (~$770 million).
Confidence: HIGH
What changedGland Pharma has secured regulatory clearance and immediately commercialized a generic version of a high-value surgical injectable in the US market.
Why it mattersThe $1.6 billion addressable market is more than double Gland's current annual revenue; even a modest market share could significantly impact the top line and support the company's 19% growth target.
US Market Size (IQVIA): $1.6 billionTTM Revenue: Rs 6,431 CrMarket Cap: Rs 40,016 CrApproval Date: July 29, 2026
📅 Short termThe immediate launch is likely to be viewed positively by the market as it demonstrates execution capability in high-value generics.
📈 Long termThis approval strengthens Gland's complex injectable portfolio and validates its B2B marketing partner strategy for regulated markets.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Pricing erosion due to generic competition
- Reliance on a marketing partner for US distribution
- Execution risk in maintaining supply for a large-volume product
Key Highlights
Received USFDA approval for Sugammadex Injection in 200 mg/2 mL and 500 mg/5 mL single-dose vials
Addressable US market size estimated at $1.6 billion for the 12 months ending April 2026
Immediate 'Day 1' launch completed through an undisclosed marketing partner
Product is bioequivalent and therapeutically equivalent to Merck's reference drug, BRIDION®
👀 What to Watch
Monitor the upcoming quarterly results for the revenue contribution from this launch and track management commentary on market share capture in the US injectable segment.
Gland Pharma Re-appoints Udo Vetter for 5 Years; Appoints William Keller to Board
Gland Pharma has announced several changes to its Board of Directors, including the re-appointment of Mr. Udo Jahannes Vetter as an Independent Director for a second five-year term effective July 21, 2026. The company also appointed Mr. William Robert Keller, who currently serves on the board of Wuxi Biologics, as an Additional Independent Director. Meanwhile, Mr. Satyanarayana Murthy Chavali has resigned to avoid potential future conflicts of interest as his own company plans to enter business segments that may overlap with Gland Pharma. Additionally, Mr. Essaji Goolam Vahanvati was appointed to the board of the company's material subsidiary, Gland Pharma International Pte. Ltd.
Key Highlights
Mr. Udo Jahannes Vetter re-appointed as Independent Director for a 5-year term until July 20, 2031.
Mr. William Robert Keller appointed as Additional Independent Director effective June 15, 2026.
Mr. Satyanarayana Murthy Chavali resigned due to potential business overlap with his own firm.
Mr. Essaji Goolam Vahanvati appointed to the board of material subsidiary Gland Pharma International Pte. Ltd.
Board committees realigned effective June 15, 2026, to reflect the new leadership structure.
👀 What to Watch
Investors should note the high caliber of the new board appointee from Wuxi Biologics and monitor the 'potential conflict of interest' mentioned by the outgoing director, as it may signal new competitive entries in Gland's niche segments.
Gland Pharma Re-appoints Udo Vetter for 5 Years; Independent Director CSN Murthy Resigns
Gland Pharma has approved the re-appointment of Mr. Udo Johannes Vetter as an Independent Director for a second five-year term from July 2026 to July 2031. Concurrently, Mr. William Robert Keller, an Independent Director at Wuxi Biologics, has been appointed as an Additional Independent Director. Notably, Mr. Satyanarayana Murthy Chavali has resigned to avoid potential conflicts of interest as his own company plans to enter business segments that may overlap with Gland Pharma's future activities. Consequently, the company has realigned its board committees and appointed Mr. Essaji Goolam Vahanvati to the board of its material subsidiary, Gland Pharma International Pte. Ltd.
Key Highlights
Re-appointment of Mr. Udo Johannes Vetter as Independent Director for a 5-year term (July 21, 2026, to July 20, 2031).
Appointment of Mr. William Robert Keller, currently on the board of Wuxi Biologics, as an Additional Independent Director.
Resignation of Mr. Satyanarayana Murthy Chavali effective June 15, 2026, citing potential future business overlap and conflict of interest.
Appointment of Mr. Essaji Goolam Vahanvati to the board of material subsidiary Gland Pharma International Pte. Ltd.
Full realignment of Board Committees effective June 15, 2026, following the management changes.
👀 What to Watch
Investors should monitor the specific business segments Gland Pharma is 'contemplating entering' as mentioned in the resignation letter, as this indicates upcoming strategic expansion. The addition of a director with Wuxi Biologics experience is a positive for global industry expertise.
Gland Pharma Q4 FY26 Revenue Up 22% to ₹17,428 Mn; CDMO Business Grows 28%
Gland Pharma reported a strong Q4 FY26 with revenue growing 22% YoY to ₹17,428 million, driven by a 28% surge in the CDMO segment. The company's US market performance was robust, growing 26% in Q4, supported by 31 new product launches throughout the fiscal year. Notably, the Cenexi acquisition has turned EBITDA positive and operationally stable, contributing EUR 45 million in Q4 revenue. Full-year adjusted PAT reached ₹10,455 million with a 16% margin, reflecting improved capacity utilization and cost-efficiency measures.
Key Highlights
Q4 FY26 revenue increased by 22% YoY to ₹17,428 million with a strong 30% adjusted EBITDA margin.
CDMO business now represents 46% of total revenue, achieving a high growth rate of 28% for the year.
Launched 31 new products in the US market during FY26, including 5 in the final quarter.
Cenexi business achieved EBITDA positivity with Q4 revenues of EUR 45 million, up 4% YoY.
Full-year FY26 consolidated revenue stood at ₹64,307 million, a 14.5% increase over the previous year.
👀 What to Watch
Investors should view the turnaround of Cenexi and the strong growth in high-margin CDMO projects as key long-term value drivers. Monitor the sustainability of the 30% EBITDA margin and the progress of the complex product pipeline in the US.
Gland Pharma Recommends ₹20 Final Dividend and Announces FY26 Audited Results
Gland Pharma's Board has recommended a final dividend of ₹20 per equity share (2000% of face value) for the financial year 2025-26. The company approved its audited financial results for the quarter and year ended March 31, 2026, with an unmodified audit opinion from Deloitte. The record date for dividend eligibility is fixed for August 11, 2026, with the 48th AGM scheduled for August 25, 2026. This substantial dividend payout indicates a strong cash position and commitment to shareholder returns.
Key Highlights
Recommended a final dividend of ₹20 per equity share (2000%) for FY 2025-26
Record date for dividend eligibility is Tuesday, August 11, 2026
Audited FY26 financial results approved with an unmodified auditor's opinion
48th Annual General Meeting (AGM) scheduled for August 25, 2026
Dividend to be paid within 30 days of shareholder approval at the AGM
👀 What to Watch
Investors should monitor the record date of August 11, 2026, to ensure eligibility for the ₹20 dividend payout. The unmodified audit report confirms financial transparency, making it a stable hold for income-seeking investors.
Gland Pharma Recommends ₹20 Final Dividend; Sets Record Date for August 11, 2026
Gland Pharma's Board of Directors has recommended a final dividend of ₹20 per equity share for the financial year 2025-26, which is 2000% of the face value of ₹1. The company has fixed August 11, 2026, as the record date to identify eligible shareholders for this payout. This announcement accompanied the approval of the company's audited financial results for the fiscal year ended March 31, 2026. The dividend is subject to shareholder approval at the 48th Annual General Meeting scheduled for August 25, 2026.
Key Highlights
Recommended a final dividend of ₹20 per equity share (2000% of face value) for FY 2025-26.
Fixed Tuesday, August 11, 2026, as the record date for dividend eligibility.
Approved audited standalone and consolidated financial results for the year ended March 31, 2026.
Statutory auditors issued an unmodified opinion on the financial statements for the fiscal year.
The 48th Annual General Meeting (AGM) is scheduled to be held on August 25, 2026.
👀 What to Watch
Investors interested in the dividend should ensure they hold the stock before the ex-dividend date, which typically falls one business day prior to the August 11 record date. Additionally, shareholders should review the full FY26 earnings report to evaluate the company's operational performance beyond the dividend payout.
Gland Pharma Q4 FY26 Results: Adjusted PAT Surges 97% YoY to ₹3,667 Million
Gland Pharma reported a robust performance for Q4 FY26, with consolidated revenue growing 22% YoY to ₹17,428 million. The company's Adjusted PAT saw a significant jump of 97% YoY, reaching ₹3,667 million, driven by improved operational efficiencies and a 153% increase in other income. For the full year FY26, revenue increased by 14% to ₹64,307 million, while Adjusted PAT grew by 50% to ₹10,455 million. The base business (Gland) also showed strong momentum with a 22% YoY revenue growth and a 45% increase in Adjusted PAT for the quarter.
Key Highlights
Consolidated Revenue for Q4 FY26 grew 22% YoY to ₹17,428 million.
Adjusted PAT for Q4 FY26 nearly doubled, rising 97% YoY to ₹3,667 million.
Adjusted EBITDA margin improved significantly to 30% in Q4 FY26 from 24% in Q4 FY25.
Full-year FY26 Revenue stood at ₹64,307 million, up 14% compared to FY25.
Base business (Gland) maintained a healthy Gross Profit margin of 62% in Q4 FY26.
👀 What to Watch
The strong growth in margins and PAT suggests a recovery in the core business and improved operational leverage. Investors should maintain a positive outlook while monitoring the sustainability of these margins and the progress of the R&D pipeline.
Gland Pharma Q4 FY26: Adj. PAT Surges 97% YoY to ₹3,667 Mn; ₹20 Dividend Declared
Gland Pharma reported a robust Q4 FY26 with consolidated revenue growing 22% YoY to ₹17,428 million, driven by strong performance in the US and Europe markets. Adjusted PAT saw a significant jump of 97% YoY to ₹3,667 million, while adjusted EBITDA margins expanded to 30% from 24% in the previous year. The CDMO segment remains a key growth driver, contributing 46% of total revenue with a 36% YoY growth rate. The board has also recommended a final dividend of ₹20 per share, reflecting strong cash flow and profitability.
Key Highlights
Consolidated Q4 revenue grew 22% YoY to ₹17,428 million, with the US market growing 24% YoY.
Adjusted PAT for Q4 FY26 surged 97% YoY to ₹3,667 million, while full-year FY26 PAT grew 50% to ₹10,455 million.
Adjusted EBITDA margin improved significantly to 30% in Q4 FY26 compared to 24% in Q4 FY25.
CDMO business showed strong momentum, contributing 46% of total revenue and growing 36% YoY in Q4.
The company launched 31 products in the USA during FY26 and filed 24 ANDAs during the year.
👀 What to Watch
Investors should view these results positively as the company demonstrates strong margin recovery and robust growth in its core US market and CDMO segment. The healthy pipeline of complex injectables and the recommended ₹20 dividend provide a positive outlook for long-term shareholders.
Gland Pharma Recommends ₹20 Final Dividend; Approves Audited FY26 Financial Results
Gland Pharma has reported its audited financial results for the fiscal year ended March 31, 2026, receiving an unmodified audit opinion from Deloitte Haskins & Sells. The Board has recommended a substantial final dividend of ₹20 per equity share (2000% of face value) for the financial year 2025-26. The record date for dividend eligibility is set for August 11, 2026, with the Annual General Meeting scheduled for August 25, 2026. The consolidated results incorporate the performance of international subsidiaries, including the Cenexi Group in Europe.
Key Highlights
Recommended a final dividend of ₹20 per equity share (2000% of face value of ₹1) for FY 2025-26.
Statutory auditors issued an unmodified opinion on both standalone and consolidated financial statements.
Record date for determining dividend eligibility is fixed as Tuesday, August 11, 2026.
The 48th Annual General Meeting (AGM) is scheduled to be held on August 25, 2026.
Consolidated results include performance from key subsidiaries like Cenexi (France) and Gland Pharma USA.
👀 What to Watch
Investors should monitor the upcoming investor presentation for detailed growth metrics in the US and European markets and note the ex-dividend date occurring around mid-August.
